l-carnitine dosage to lower lp a New insights into the therapeutic options lipoprotein(a) - Baragetti - 2024 - European Journal of Clinical Investigation Lp(a) and CVD Risk: Essential

Our team of dedicated professionals endeavors to deliver personalized, compassionate, and cutting-edge medical services, tailored to meet your unique healthcare needs

Therefore, the addition of trehalose as a pharmaceutically acceptable additive for the preparation of a pharmaceutical composition, in particular, in the form of tablets or capsules, is another important aspect of the present invention

Zhou, W., Triche, T

The pharmaceutical formulation of any one of claims 1-12, wherein the compound of Formula I, Formula la, or Formula lb is present in an amount of about 10 mg to about 200 mg per one mL of the pharmaceutical formulation

By linking metabolic dysfunction, and specifically obesity-related adipokines, to local inflammation and tissue destruction strongly sustained by metalloproteinases (MMPs) and their inhibitors (Tissue Inhibitors of MetalloproteinasesTIMPs), we aim to outline translational strategies for precision-guided therapies in HS and to highlight future directions focused at integrating the influence of the "gut-skin axis" and metabolic factors on HS pathogenesis and the optimal response to drugs